Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

U.S. judge grants Purdue Pharma's $7 million exec bonus plan, faces blunt criticism

Stock MarketsSep 13, 2021 05:51PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: A pharmacist holds a bottle OxyContin made by Purdue Pharma, at a pharmacy in Provo, Utah, U.S., May 9, 2019. REUTERS/George Frey/File Photo

By Maria Chutchian

(Reuters) -A U.S. judge on Monday approved up to $7.1 million in bonuses for five executives of Purdue Pharma, the bankrupt maker of OxyContin, at a hearing at which he faced blunt criticism for his handling of the case from a woman whose son died of an opioid overdose.

U.S. Bankruptcy Judge Robert Drain in White Plains, New York, signed off on the executive incentive plan at the conclusion of the virtual hearing.

His ruling comes about two weeks after he said he would approve Purdue’s reorganization plan, which rests on a $10 billion settlement of opioid-related lawsuits and provides legal releases shielding the Sackler family members that owned the company from future opioid-related civil litigation.

The Sacklers contributed approximately $4.5 billion to the plan, which had wide support from creditors who voted on it, but critics have been angered that the family will retain billion of dollars and never face a public civil trial.

"OxyContin tore our family to shreds," Ellen Isaacs, whose son died of an opioid overdose, told Drain during Monday's hearing, urging him to approve her motion to reconsider his ruling and recuse himself from the case.

More than 500,000 Americans have died since 1999 from opioid overdoses, according to the Centers for Disease Control and Prevention.

During a 30-minute statement to the court, Isaacs delivered a rare courtroom reprimand to the judge, saying it's "well known" that the bankruptcy was filed before Drain because the Sacklers knew he had a history of approving releases like the one they sought.

She also said the Sacklers, who have denied wrongdoing, should face criminal charges and that victims and their families are being allocated too little through Purdue's plan.

Drain denied her request and said that while he has “no love lost for the Sacklers,” he did not feel “manipulated by anyone” in the case. He also noted that the releases, which he said are supported by many courts across the country, do not protect the Sacklers against potential criminal liability.

A representative for the Mortimer Sackler family referred a request for comment to a prior statement disputing allegations made about the family and saying it is "truly sorry for the suffering and loss people have experienced and recognize the anger or hurt that many people have felt."

The total incentive payments for Purdue executives for 2021 is $4 million to $5.4 million, depending on their ability to meet their goals as they continue to work toward a bankruptcy exit. They could also collect up to an additional $1.7 million in long-term incentives. The executives would have to meet targets related to operating profits, net sales and deadlines for testing and development of non-opioid products.

Drain said he did not consider the incentive payments he was approving “bonuses” because even if paid out in full, they would still only fall in the middle of the total compensation range for executives at major pharmaceutical companies.

“No doubt my ruling will be construed by some as authorizing large bonuses to executives. I do not believe that is in fact the case here,” he said.

U.S. judge grants Purdue Pharma's $7 million exec bonus plan, faces blunt criticism

Related Articles

4 Dow Stocks to Add to Your Portfolio in December
4 Dow Stocks to Add to Your Portfolio in December By StockNews - Dec 02, 2021

Better-than-expected private payrolls, high consumer spending, and strategic policies to deal with the COVID-19 omicron variant are expected to support the stock market. Therefore,...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Me comment
Me comment Sep 13, 2021 3:54PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Give the money to the victim families not the pharmaceuticals excecutives
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email